These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 25433556)

  • 1. Patterns of progression in pediatric patients with high-grade glioma or diffuse intrinsic pontine glioma treated with Bevacizumab-based therapy at diagnosis.
    Salloum R; DeWire M; Lane A; Goldman S; Hummel T; Chow L; Miles L; Sutton M; Stevenson C; Fouladi M; Leach J
    J Neurooncol; 2015 Feb; 121(3):591-8. PubMed ID: 25433556
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A pilot study of bevacizumab-based therapy in patients with newly diagnosed high-grade gliomas and diffuse intrinsic pontine gliomas.
    Hummel TR; Salloum R; Drissi R; Kumar S; Sobo M; Goldman S; Pai A; Leach J; Lane A; Pruitt D; Sutton M; Chow LM; Grimme L; Doughman R; Backus L; Miles L; Stevenson C; Fouladi M; DeWire M
    J Neurooncol; 2016 Mar; 127(1):53-61. PubMed ID: 26626490
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lack of efficacy of bevacizumab plus irinotecan in children with recurrent malignant glioma and diffuse brainstem glioma: a Pediatric Brain Tumor Consortium study.
    Gururangan S; Chi SN; Young Poussaint T; Onar-Thomas A; Gilbertson RJ; Vajapeyam S; Friedman HS; Packer RJ; Rood BN; Boyett JM; Kun LE
    J Clin Oncol; 2010 Jun; 28(18):3069-75. PubMed ID: 20479404
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of bevacizumab plus irinotecan in children with recurrent low-grade gliomas--a Pediatric Brain Tumor Consortium study.
    Gururangan S; Fangusaro J; Poussaint TY; McLendon RE; Onar-Thomas A; Wu S; Packer RJ; Banerjee A; Gilbertson RJ; Fahey F; Vajapeyam S; Jakacki R; Gajjar A; Goldman S; Pollack IF; Friedman HS; Boyett JM; Fouladi M; Kun LE
    Neuro Oncol; 2014 Jan; 16(2):310-7. PubMed ID: 24311632
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bevacizumab in recurrent high-grade pediatric gliomas.
    Narayana A; Kunnakkat S; Chacko-Mathew J; Gardner S; Karajannis M; Raza S; Wisoff J; Weiner H; Harter D; Allen J
    Neuro Oncol; 2010 Sep; 12(9):985-90. PubMed ID: 20363768
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase 2 study of valproic acid and radiation, followed by maintenance valproic acid and bevacizumab in children with newly diagnosed diffuse intrinsic pontine glioma or high-grade glioma.
    Su JM; Murray JC; McNall-Knapp RY; Bowers DC; Shah S; Adesina AM; Paulino AC; Jo E; Mo Q; Baxter PA; Blaney SM
    Pediatr Blood Cancer; 2020 Jun; 67(6):e28283. PubMed ID: 32285998
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Surgery for Recurrent High-Grade Glioma After Treatment with Bevacizumab.
    Blumenthal DT; Kanner AA; Aizenstein O; Cagnano E; Greenberg A; Hershkovitz D; Ram Z; Bokstein F
    World Neurosurg; 2018 Feb; 110():e727-e737. PubMed ID: 29183864
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pseudoprogression in children, adolescents and young adults with non-brainstem high grade glioma and diffuse intrinsic pontine glioma.
    Carceller F; Fowkes LA; Khabra K; Moreno L; Saran F; Burford A; Mackay A; Jones DT; Hovestadt V; Marshall LV; Vaidya S; Mandeville H; Jerome N; Bridges LR; Laxton R; Al-Sarraj S; Pfister SM; Leach MO; Pearson AD; Jones C; Koh DM; Zacharoulis S
    J Neurooncol; 2016 Aug; 129(1):109-21. PubMed ID: 27180091
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Invasion is not an independent prognostic factor in high-grade glioma.
    Narayana A; Perretta D; Kunnakkat S; Gruber D; Golfinos J; Parker E; Medabalmi P; Zagzag D; Pat Eagan RN; Gruber M
    J Cancer Res Ther; 2011; 7(3):331-5. PubMed ID: 22044816
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Confirmation of Bevacizumab Activity, and Maintenance of Efficacy in Retreatment After Subsequent Relapse, in Pediatric Low-grade Glioma.
    Kalra M; Heath JA; Kellie SJ; Dalla Pozza L; Stevens MM; Swamy S; McCowage GB
    J Pediatr Hematol Oncol; 2015 Aug; 37(6):e341-6. PubMed ID: 26056795
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nimotuzumab-containing regimen for pediatric diffuse intrinsic pontine gliomas: a retrospective multicenter study and review of the literature.
    Kebudi R; Cakir FB; Bay SB; Gorgun O; Altınok P; Iribas A; Agaoglu FY; Darendeliler E
    Childs Nerv Syst; 2019 Jan; 35(1):83-89. PubMed ID: 30417211
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of children with diffuse intrinsic pontine gliomas with chemoradiotherapy followed by a combination of temozolomide, irinotecan, and bevacizumab.
    Zaky W; Wellner M; Brown RJ; Blüml S; Finlay JL; Dhall G
    Pediatr Hematol Oncol; 2013 Oct; 30(7):623-32. PubMed ID: 24050762
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Retrospective review of safety and efficacy of programmed cell death-1 inhibitors in refractory high grade gliomas.
    Reiss SN; Yerram P; Modelevsky L; Grommes C
    J Immunother Cancer; 2017 Dec; 5(1):99. PubMed ID: 29254497
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bevacizumab (BVZ)-associated toxicities in children with recurrent central nervous system tumors treated with BVZ and irinotecan (CPT-11): a Pediatric Brain Tumor Consortium Study (PBTC-022).
    Fangusaro J; Gururangan S; Poussaint TY; McLendon RE; Onar-Thomas A; Warren KE; Wu S; Packer RJ; Banerjee A; Gilbertson RJ; Jakacki R; Gajjar A; Goldman S; Pollack IF; Friedman HS; Boyett JM; Kun LE; Fouladi M
    Cancer; 2013 Dec; 119(23):4180-7. PubMed ID: 24104527
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Bevacizumab/irinotecan. An active treatment for recurrent high grade gliomas: preliminary results of an ANOCEF Multicenter Study].
    Guiu S; Taillibert S; Chinot O; Taillandier L; Honnorat J; Dietrich PY; Maire JP; Guillamo JS; Guiu B; Catry-Thomas I; Capelle F; Thiebaut A; Cartalat-Carel S; Deville C; Fumoleau P; Desjardins A; Xuan KH; Chauffert B
    Rev Neurol (Paris); 2008; 164(6-7):588-94. PubMed ID: 18565358
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Primary dissemination of high-grade gliomas in children: experiences from four studies of the Pediatric Oncology and Hematology Society of the German Language Group (GPOH).
    Benesch M; Wagner S; Berthold F; Wolff JE
    J Neurooncol; 2005 Apr; 72(2):179-83. PubMed ID: 15925999
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Change in pattern of relapse after antiangiogenic therapy in high-grade glioma.
    Narayana A; Kunnakkat SD; Medabalmi P; Golfinos J; Parker E; Knopp E; Zagzag D; Eagan P; Gruber D; Gruber ML
    Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):77-82. PubMed ID: 21163583
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FLAIR-only progression in bevacizumab-treated relapsing glioblastoma does not predict short survival.
    Schaub C; Greschus S; Seifert M; Waha A; Blasius E; Rasch K; Landwehr C; Mack F; Schäfer N; Stuplich M; Kebir S; Vilz B; Scheffler B; Boström J; Simon M; Urbach H; Glas M; Herrlinger U
    Oncology; 2013; 85(3):191-5. PubMed ID: 24008924
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A pediatric trial of radiation/cetuximab followed by irinotecan/cetuximab in newly diagnosed diffuse pontine gliomas and high-grade astrocytomas: A Pediatric Oncology Experimental Therapeutics Investigators' Consortium study.
    Macy ME; Kieran MW; Chi SN; Cohen KJ; MacDonald TJ; Smith AA; Etzl MM; Kuei MC; Donson AM; Gore L; DiRenzo J; Trippett TM; Ostrovnaya I; Narendran A; Foreman NK; Dunkel IJ
    Pediatr Blood Cancer; 2017 Nov; 64(11):. PubMed ID: 28544128
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Calcification in high grade gliomas treated with bevacizumab.
    Blumenthal DT; Aisenstein O; Ben-Horin I; Ben Bashat D; Artzi M; Corn BW; Kanner AA; Ram Z; Bokstein F
    J Neurooncol; 2015 Jun; 123(2):283-8. PubMed ID: 25939440
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.